Dr. Oliver Daumke of MDC wins Bayer Early Excellence in Science Award

November 22, 2010

Biochemist and protein crystallographer Dr. Oliver Daumke of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch, Germany, has won the "Bayer Early Excellence in Science Award 2010" in the biology category. He will receive the prize worth EUR 10,000 for his contributions to the understanding of the structure and function of GTP-binding (G) proteins next spring in Berlin. Together with him, two other scientists, Professor Nicolai Cramer (Lausanne, Switzerland) and Dr. Andreas Walther (Helsinki, Finland) will also be honored and receive EUR 10,000 each. G proteins play an important role in cellular signaling pathways and in the defense against infections. The Bayer Foundation presents this award to talented young scientists in the early stages of their academic careers.

G proteins can act as molecular switches that control growth signals in biological cells. Other G proteins function as molecular motors that deform cellular membranes. The group headed by Dr. Daumke investigates the differences and similarities between these two classes of G proteins. The researchers hope that their findings will help develop new strategies to treat diseases such as cancer, diabetes or flu.

Only recently, Dr. Daumke - together with virologists in Freiburg, Germany - elucidated how the human immune system is activated to fight against new, unknown flu viruses. They showed how a G protein called MxA stops flu viruses from replicating.

Dr. Daumke came to the MDC in 2007 as Helmholtz Young Investigator. Prior to his position in Berlin he was a researcher at the Laboratory for Molecular Biology in Cambridge (England). In September this year he was named Junior Professor at the Charité - Universitätsmedizin Berlin. His previous awards include a grant within the Human Frontier Science Program, the Otto Hahn Medal of the Max Planck Society and the Klaus Liebrecht Prize for the best PhD thesis at the University of Cologne.
-end-
Barbara Bachtler
Press and Public Affairs
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
Robert-Rössle-Straße 10; 13125 Berlin; Germany
Phone: +49 (0) 30 94 06 - 38 96
Fax: +49 (0) 30 94 06 - 38 33
e-mail: presse@mdc-berlin.de
http://www.mdc-berlin.de/

Further information:
http://www.bayer.com/en/homepage.aspx
http://www.mdc-berlin.de/en/news/2010/20100427-a_clamp_for_emerging_flu_viruses/index.html

Helmholtz Association

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.